The Asia Pacific Vaccine Adjuvants Market would witness market growth of 4.0% CAGR during the forecast period (2023-2030).
Mucosal vaccines possess considerable promise and merit in mitigating infections induced by various pathogens. When developing mucosal vaccines, the most formidable obstacle is identifying adjuvants and drug delivery methods that are both safe and productive. Significant advancements have been achieved in developing mucosal adjuvants through the utilization of diverse vaccine delivery systems, detoxified bacteria toxin derivatives, pathogen-related molecules, and cytokines. Moreover, specific natural substances can enhance the immune response and may be used as vaccination adjuvants. Natural product-based immune adjuvants possess several benefits compared to conventional adjuvants, including low production costs, high stability, and low toxicity.
A significant number of pathogens, including influenza viruses, human papillomavirus (HPV), HIV, and the malaria parasite, exhibit either strain variations or substantial antigenic drift. Consequently, adjuvants' capacity to expand the profile of an immune response may be critical to the efficacy of vaccines designed to combat such targets. Experimentally, massively parallel sequencing has demonstrated that increased titers and the expansion of B cell diversity may mediate adjuvants' expanding effect. Adjuvant-induced antibody response diversification in the influenza and HPV vaccines has been proven in clinical settings.
By approximately 2050, China is projected to have 487 million citizens aged 60 or older, as reported by the Office of the National Working Commission on Aging. Furthermore, the State Council of the People's Republic of China reported that the nation has increased its efforts in recent years to promote the integration of medical and geriatric care services, advance diversified long-term care services based on community and home, and conduct trials for long-term care insurance. Thus, the demand for market may experience an upward trajectory with the aging population, as greater emphasis may be placed on developing and utilizing vaccines that demonstrate enhanced efficacy among the older population.
The China market dominated the Asia Pacific Vaccine Adjuvants Market, by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $143.7 Million by 2030. The Japan market is registering a CAGR of 3.3% during (2023 - 2030). Additionally, The India market would showcase a CAGR of 4.7% during (2023 - 2030).
Based on Type, the market is segmented into Particulate, Adjuvant Emulsion, Pathogen, Combination, and Others. Based on Administration, the market is segmented into Intramuscular, Intranasal, Oral, Intradermal, and Others. Based on Application, the market is segmented into Infectious Diseases, Cancer, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Global Vaccine Adjuvants Market is Predict to reach $2.1 Billion by 2030, at a CAGR of 3.7%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GlaxoSmithKline PLC, Novavax, Inc., SPI Pharma, Inc. (Associated British Foods PLC), Agenus Inc., CSL Limited, InvivoGen SAS, Croda International PLC, Seppic S.A. (L’Air Liquide S.A.), Merck & Co., Inc. and Riboxx GmbH
Scope of the Study
Market Segments Covered in the Report:
By Type
- Particulate
- Adjuvant Emulsion
- Pathogen
- Combination
- Others
By Administration
- Intramuscular
- Intranasal
- Oral
- Intradermal
- Others
By Application
- Infectious Diseases
- Cancer
- Others
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- GlaxoSmithKline PLC
- Novavax, Inc.
- SPI Pharma, Inc. (Associated British Foods PLC)
- Agenus Inc.
- CSL Limited
- InvivoGen SAS
- Croda International PLC
- Seppic S.A. (L’Air Liquide S.A.)
- Merck & Co., Inc.
- Riboxx GmbH
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Vaccine Adjuvants Market, by Type
1.4.2 Asia Pacific Vaccine Adjuvants Market, by Administration
1.4.3 Asia Pacific Vaccine Adjuvants Market, by Application
1.4.4 Asia Pacific Vaccine Adjuvants Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
Chapter 4. Competition Analysis - Global
4.1 KBV Cardinal Matrix
4.2 Recent Industry Wide Strategic Developments
4.2.1 Partnerships, Collaborations and Agreements
4.2.2 Product Launches and Product Expansions
4.2.3 Acquisition and Mergers
4.2.4 Trials and Approvals
4.3 Top Winning Strategies
4.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
4.3.2 Key Strategic Move: (Partnerships, Collaborations & Agreements: 2020, Feb – 2023, Oct) Leading Players
4.4 Porter Five Forces Analysis
Chapter 5. Asia Pacific Vaccine Adjuvants Market, by Type
5.1 Asia Pacific Particulate Market, by Country
5.2 Asia Pacific Adjuvant Emulsion Market, by Country
5.3 Asia Pacific Pathogen Market, by Country
5.4 Asia Pacific Combination Market, by Country
5.5 Asia Pacific Others Market, by Country
Chapter 6. Asia Pacific Vaccine Adjuvants Market, by Administration
6.1 Asia Pacific Intramuscular Market, by Country
6.2 Asia Pacific Intranasal Market, by Country
6.3 Asia Pacific Oral Market, by Country
6.4 Asia Pacific Intradermal Market, by Country
6.5 Asia Pacific Others Market, by Country
Chapter 7. Asia Pacific Vaccine Adjuvants Market, by Application
7.1 Asia Pacific Infectious Diseases Market, by Country
7.2 Asia Pacific Cancer Market, by Country
7.3 Asia Pacific Others Market, by Country
Chapter 8. Asia Pacific Vaccine Adjuvants Market, by Country
8.1 China Vaccine Adjuvants Market
8.1.1 China Vaccine Adjuvants Market, by Type
8.1.2 China Vaccine Adjuvants Market, by Administration
8.1.3 China Vaccine Adjuvants Market, by Application
8.2 Japan Vaccine Adjuvants Market
8.2.1 Japan Vaccine Adjuvants Market, by Type
8.2.2 Japan Vaccine Adjuvants Market, by Administration
8.2.3 Japan Vaccine Adjuvants Market, by Application
8.3 India Vaccine Adjuvants Market
8.3.1 India Vaccine Adjuvants Market, by Type
8.3.2 India Vaccine Adjuvants Market, by Administration
8.3.3 India Vaccine Adjuvants Market, by Application
8.4 South Korea Vaccine Adjuvants Market
8.4.1 South Korea Vaccine Adjuvants Market, by Type
8.4.2 South Korea Vaccine Adjuvants Market, by Administration
8.4.3 South Korea Vaccine Adjuvants Market, by Application
8.5 Singapore Vaccine Adjuvants Market
8.5.1 Singapore Vaccine Adjuvants Market, by Type
8.5.2 Singapore Vaccine Adjuvants Market, by Administration
8.5.3 Singapore Vaccine Adjuvants Market, by Application
8.6 Malaysia Vaccine Adjuvants Market
8.6.1 Malaysia Vaccine Adjuvants Market, by Type
8.6.2 Malaysia Vaccine Adjuvants Market, by Administration
8.6.3 Malaysia Vaccine Adjuvants Market, by Application
8.7 Rest of Asia Pacific Vaccine Adjuvants Market
8.7.1 Rest of Asia Pacific Vaccine Adjuvants Market, by Type
8.7.2 Rest of Asia Pacific Vaccine Adjuvants Market, by Administration
8.7.3 Rest of Asia Pacific Vaccine Adjuvants Market, by Application
Chapter 9. Company Profiles
9.1 Novavax, Inc.
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Segmental and Regional Analysis
9.1.4 Research & Development Expenses
9.1.5 Recent strategies and developments:
9.1.5.1 Partnerships, Collaborations, and Agreements:
9.1.6 SWOT Analysis
9.2 SPI Pharma, Inc. (Associated British Foods PLC)
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Segmental and Regional Analysis
9.2.4 Research & Development Expenses
9.2.5 Recent strategies and developments:
9.2.5.1 Partnerships, Collaborations, and Agreements:
9.3 Agenus Inc.
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Regional Analysis
9.3.4 Research & Development Expenses
9.3.5 Recent strategies and developments:
9.3.5.1 Partnerships, Collaborations, and Agreements:
9.3.6 SWOT Analysis
9.4 InvivoGen SAS
9.4.1 Company Overview
9.4.2 SWOT Analysis
9.5 Seppic S.A. (L’Air Liquide S.A.)
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Segmental and Regional Analysis
9.5.4 Research & Development Expenses
9.5.5 Recent strategies and developments:
9.5.5.1 Product Launches and Product Expansions:
9.5.6 SWOT Analysis
9.6 Riboxx GmbH
9.6.1 Company Overview
9.7 GlaxoSmithKline PLC (GSK)
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Regional Analysis
9.7.4 Research & Development Expense
9.7.5 Recent strategies and developments:
9.7.5.1 Partnerships, Collaborations, and Agreements:
9.7.5.2 Product Launches and Product Expansions:
9.7.5.3 Trials and Approvals:
9.7.6 SWOT Analysis
9.8 CSL Limited
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Segmental and Regional Analysis
9.8.4 Research & Development Expenses
9.8.5 Recent strategies and developments:
9.8.5.1 Partnerships, Collaborations, and Agreements:
9.8.6 SWOT Analysis
9.9 Croda International PLC
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Segmental and Regional Analysis
9.9.4 Recent strategies and developments:
9.9.4.1 Partnerships, Collaborations, and Agreements:
9.9.4.2 Acquisition and Mergers:
9.10. Merck & Co., Inc.
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Segmental and Regional Analysis
9.10.4 Research & Development Expenses
9.10.5 Recent strategies and developments:
9.10.5.1 Acquisition and Mergers:
9.10.6 SWOT Analysis
TABLE 1 Asia Pacific Vaccine Adjuvants Market, 2019 - 2022, USD Million
TABLE 2 Asia Pacific Vaccine Adjuvants Market, 2023 - 2030, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Vaccine Adjuvants Market
TABLE 4 Product Launches And Product Expansions– Vaccine Adjuvants Market
TABLE 5 Acquisition and Mergers– Vaccine Adjuvants Market
TABLE 6 Trials and Approvals- Vaccine Adjuvants Market
TABLE 7 Asia Pacific Vaccine Adjuvants Market, by Type, 2019 - 2022, USD Million
TABLE 8 Asia Pacific Vaccine Adjuvants Market, by Type, 2023 - 2030, USD Million
TABLE 9 Asia Pacific Particulate Market, by Country, 2019 - 2022, USD Million
TABLE 10 Asia Pacific Particulate Market, by Country, 2023 - 2030, USD Million
TABLE 11 Asia Pacific Adjuvant Emulsion Market, by Country, 2019 - 2022, USD Million
TABLE 12 Asia Pacific Adjuvant Emulsion Market, by Country, 2023 - 2030, USD Million
TABLE 13 Asia Pacific Pathogen Market, by Country, 2019 - 2022, USD Million
TABLE 14 Asia Pacific Pathogen Market, by Country, 2023 - 2030, USD Million
TABLE 15 Asia Pacific Combination Market, by Country, 2019 - 2022, USD Million
TABLE 16 Asia Pacific Combination Market, by Country, 2023 - 2030, USD Million
TABLE 17 Asia Pacific Others Market, by Country, 2019 - 2022, USD Million
TABLE 18 Asia Pacific Others Market, by Country, 2023 - 2030, USD Million
TABLE 19 Asia Pacific Vaccine Adjuvants Market, by Administration, 2019 - 2022, USD Million
TABLE 20 Asia Pacific Vaccine Adjuvants Market, by Administration, 2023 - 2030, USD Million
TABLE 21 Asia Pacific Intramuscular Market, by Country, 2019 - 2022, USD Million
TABLE 22 Asia Pacific Intramuscular Market, by Country, 2023 - 2030, USD Million
TABLE 23 Asia Pacific Intranasal Market, by Country, 2019 - 2022, USD Million
TABLE 24 Asia Pacific Intranasal Market, by Country, 2023 - 2030, USD Million
TABLE 25 Asia Pacific Oral Market, by Country, 2019 - 2022, USD Million
TABLE 26 Asia Pacific Oral Market, by Country, 2023 - 2030, USD Million
TABLE 27 Asia Pacific Intradermal Market, by Country, 2019 - 2022, USD Million
TABLE 28 Asia Pacific Intradermal Market, by Country, 2023 - 2030, USD Million
TABLE 29 Asia Pacific Others Market, by Country, 2019 - 2022, USD Million
TABLE 30 Asia Pacific Others Market, by Country, 2023 - 2030, USD Million
TABLE 31 Asia Pacific Vaccine Adjuvants Market, by Application, 2019 - 2022, USD Million
TABLE 32 Asia Pacific Vaccine Adjuvants Market, by Application, 2023 - 2030, USD Million
TABLE 33 Asia Pacific Infectious Diseases Market, by Country, 2019 - 2022, USD Million
TABLE 34 Asia Pacific Infectious Diseases Market, by Country, 2023 - 2030, USD Million
TABLE 35 Asia Pacific Cancer Market, by Country, 2019 - 2022, USD Million
TABLE 36 Asia Pacific Cancer Market, by Country, 2023 - 2030, USD Million
TABLE 37 Asia Pacific Others Market, by Country, 2019 - 2022, USD Million
TABLE 38 Asia Pacific Others Market, by Country, 2023 - 2030, USD Million
TABLE 39 Asia Pacific Vaccine Adjuvants Market, by Country, 2019 - 2022, USD Million
TABLE 40 Asia Pacific Vaccine Adjuvants Market, by Country, 2023 - 2030, USD Million
TABLE 41 China Vaccine Adjuvants Market, 2019 - 2022, USD Million
TABLE 42 China Vaccine Adjuvants Market, 2023 - 2030, USD Million
TABLE 43 China Vaccine Adjuvants Market, by Type, 2019 - 2022, USD Million
TABLE 44 China Vaccine Adjuvants Market, by Type, 2023 - 2030, USD Million
TABLE 45 China Vaccine Adjuvants Market, by Administration, 2019 - 2022, USD Million
TABLE 46 China Vaccine Adjuvants Market, by Administration, 2023 - 2030, USD Million
TABLE 47 China Vaccine Adjuvants Market, by Application, 2019 - 2022, USD Million
TABLE 48 China Vaccine Adjuvants Market, by Application, 2023 - 2030, USD Million
TABLE 49 Japan Vaccine Adjuvants Market, 2019 - 2022, USD Million
TABLE 50 Japan Vaccine Adjuvants Market, 2023 - 2030, USD Million
TABLE 51 Japan Vaccine Adjuvants Market, by Type, 2019 - 2022, USD Million
TABLE 52 Japan Vaccine Adjuvants Market, by Type, 2023 - 2030, USD Million
TABLE 53 Japan Vaccine Adjuvants Market, by Administration, 2019 - 2022, USD Million
TABLE 54 Japan Vaccine Adjuvants Market, by Administration, 2023 - 2030, USD Million
TABLE 55 Japan Vaccine Adjuvants Market, by Application, 2019 - 2022, USD Million
TABLE 56 Japan Vaccine Adjuvants Market, by Application, 2023 - 2030, USD Million
TABLE 57 India Vaccine Adjuvants Market, 2019 - 2022, USD Million
TABLE 58 India Vaccine Adjuvants Market, 2023 - 2030, USD Million
TABLE 59 India Vaccine Adjuvants Market, by Type, 2019 - 2022, USD Million
TABLE 60 India Vaccine Adjuvants Market, by Type, 2023 - 2030, USD Million
TABLE 61 India Vaccine Adjuvants Market, by Administration, 2019 - 2022, USD Million
TABLE 62 India Vaccine Adjuvants Market, by Administration, 2023 - 2030, USD Million
TABLE 63 India Vaccine Adjuvants Market, by Application, 2019 - 2022, USD Million
TABLE 64 India Vaccine Adjuvants Market, by Application, 2023 - 2030, USD Million
TABLE 65 South Korea Vaccine Adjuvants Market, 2019 - 2022, USD Million
TABLE 66 South Korea Vaccine Adjuvants Market, 2023 - 2030, USD Million
TABLE 67 South Korea Vaccine Adjuvants Market, by Type, 2019 - 2022, USD Million
TABLE 68 South Korea Vaccine Adjuvants Market, by Type, 2023 - 2030, USD Million
TABLE 69 South Korea Vaccine Adjuvants Market, by Administration, 2019 - 2022, USD Million
TABLE 70 South Korea Vaccine Adjuvants Market, by Administration, 2023 - 2030, USD Million
TABLE 71 South Korea Vaccine Adjuvants Market, by Application, 2019 - 2022, USD Million
TABLE 72 South Korea Vaccine Adjuvants Market, by Application, 2023 - 2030, USD Million
TABLE 73 Singapore Vaccine Adjuvants Market, 2019 - 2022, USD Million
TABLE 74 Singapore Vaccine Adjuvants Market, 2023 - 2030, USD Million
TABLE 75 Singapore Vaccine Adjuvants Market, by Type, 2019 - 2022, USD Million
TABLE 76 Singapore Vaccine Adjuvants Market, by Type, 2023 - 2030, USD Million
TABLE 77 Singapore Vaccine Adjuvants Market, by Administration, 2019 - 2022, USD Million
TABLE 78 Singapore Vaccine Adjuvants Market, by Administration, 2023 - 2030, USD Million
TABLE 79 Singapore Vaccine Adjuvants Market, by Application, 2019 - 2022, USD Million
TABLE 80 Singapore Vaccine Adjuvants Market, by Application, 2023 - 2030, USD Million
TABLE 81 Malaysia Vaccine Adjuvants Market, 2019 - 2022, USD Million
TABLE 82 Malaysia Vaccine Adjuvants Market, 2023 - 2030, USD Million
TABLE 83 Malaysia Vaccine Adjuvants Market, by Type, 2019 - 2022, USD Million
TABLE 84 Malaysia Vaccine Adjuvants Market, by Type, 2023 - 2030, USD Million
TABLE 85 Malaysia Vaccine Adjuvants Market, by Administration, 2019 - 2022, USD Million
TABLE 86 Malaysia Vaccine Adjuvants Market, by Administration, 2023 - 2030, USD Million
TABLE 87 Malaysia Vaccine Adjuvants Market, by Application, 2019 - 2022, USD Million
TABLE 88 Malaysia Vaccine Adjuvants Market, by Application, 2023 - 2030, USD Million
TABLE 89 Rest of Asia Pacific Vaccine Adjuvants Market, 2019 - 2022, USD Million
TABLE 90 Rest of Asia Pacific Vaccine Adjuvants Market, 2023 - 2030, USD Million
TABLE 91 Rest of Asia Pacific Vaccine Adjuvants Market, by Type, 2019 - 2022, USD Million
TABLE 92 Rest of Asia Pacific Vaccine Adjuvants Market, by Type, 2023 - 2030, USD Million
TABLE 93 Rest of Asia Pacific Vaccine Adjuvants Market, by Administration, 2019 - 2022, USD Million
TABLE 94 Rest of Asia Pacific Vaccine Adjuvants Market, by Administration, 2023 - 2030, USD Million
TABLE 95 Rest of Asia Pacific Vaccine Adjuvants Market, by Application, 2019 - 2022, USD Million
TABLE 96 Rest of Asia Pacific Vaccine Adjuvants Market, by Application, 2023 - 2030, USD Million
TABLE 97 Key Information – Novavax, Inc.
TABLE 98 Key Information – SPI Pharma, Inc.
TABLE 99 Key Information – Agenus Inc.
TABLE 100 Key Information – InvivoGen SAS
TABLE 101 Key Information – Seppic S.A.
TABLE 102 Key Information – Riboxx GmbH
TABLE 103 Key Information – GlaxoSmithKline PLC
TABLE 104 Key Information – CSL Limited
TABLE 105 Key Information – Croda International PLC
TABLE 106 Key Information - Merck & Co., Inc.
List of Figures
FIG 1 Methodology for the research
FIG 2 Asia Pacific Vaccine Adjuvants Market, 2019 - 2030, USD Million
FIG 3 Key Factors Impacting the Vaccine Adjuvants Market
FIG 4 KBV Cardinal Matrix
FIG 5 Key Leading Strategies: Percentage Distribution (2019-2023)
FIG 6 Key Strategic Move: (Product Launches and Product Expansions : 2017, Jun – 2021, Jun) Leading Players
FIG 7 Porter’s Five Forces Analysis – Vaccine Adjuvants Market
FIG 8 Asia Pacific Vaccine Adjuvants Market share, by Type, 2022
FIG 9 Asia Pacific Vaccine Adjuvants Market share, by Type, 2030
FIG 10 Asia Pacific Vaccine Adjuvants Market, by Type, 2019 - 2030, USD Million
FIG 11 Asia Pacific Vaccine Adjuvants Market share, by Administration, 2022
FIG 12 Asia Pacific Vaccine Adjuvants Market share, by Administration, 2030
FIG 13 Asia Pacific Vaccine Adjuvants Market, by Administration, 2019 - 2030, USD Million
FIG 14 Asia Pacific Vaccine Adjuvants Market share, by Application, 2022
FIG 15 Asia Pacific Vaccine Adjuvants Market share, by Application, 2030
FIG 16 Asia Pacific Vaccine Adjuvants Market, by Application, 2019 - 2030, USD Million
FIG 17 Asia Pacific Vaccine Adjuvants Market share, by Country, 2022
FIG 18 Asia Pacific Vaccine Adjuvants Market share, by Country, 2030
FIG 19 Asia Pacific Vaccine Adjuvants Market, by Country, 2019 - 2030, USD Million
FIG 20 SWOT Analysis: Novavax, Inc.
FIG 21 SWOT Analysis: Agenus Inc.
FIG 22 SWOT Analysis: InvivoGen SAS
FIG 23 SWOT Analysis: Seppic S.A.
FIG 24 Recent strategies and developments: GlaxoSmithKline PLC
FIG 25 SWOT Analysis: GlaxoSmithKline PLC
FIG 26 SWOT Analysis: CSL Limited
FIG 27 SWOT Analysis: Merck & Co., Inc.